COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Nation gears up for Spring Festival rush
- China, Philippines to keep talks open on maritime affairs
- AI governance tops China’s 2025 technology buzzwords list
- China-Swiss exhibition on green construction opens
- China says navy, coast guard are peace guardians
- Hunan scholar donates 104 artifacts documenting Japanese aggression
